Effect of introducing high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children
This is the main finding of a recent article based on data from The Streptococcus pneumoniae Invasive Disease network (SpIDnet).
Pneumococcal meningitis in French children before and after the introduction of pneumococcal conjugate vaccineArchived
In the context of an active nationwide surveillance network, this study describes pneumoccocal meningitis in children aged from 1 day to 15 years during a 8 year study period (2001-2008) in France. 951 pneumoccocal meningitis cases were reported among 3312 children with bacterial meningitis. T
Serotype replacement in disease after pneumococcal vaccinationArchived
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.
Are statins protective in patients with severe respiratory infections? Two new studies from EuropeArchived
In recent years there have been a series of arguments and findings suggesting that Statins (HMG-CoA reductase inhibitors) which used widely to lower cholesterol levels may also be important in reducing the risk associated with severe infective conditions.
Paediatric pneumococcal disease in Central EuropeArchived
The authors present an appraisal of the pneumococcal epidemiological situation in 11 Central European countries. Data are based on study findings presented at the 12th Central European Vaccine Advisory Group (CEVAG) meeting, held on 21–22 May 2010 in Sofia, Bulgaria, and a literature review of the PubMed database.
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate VaccineArchived
This study demonstrates that PCV13 is immunogenic and safe in children previously vaccinated with PCV7. By eliciting high antibacterial immune responses to the additional serotypes, PCV13 provides protection against these serotypes, which are important causes of pneumococcal disease globally.
Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in FranceArchived
This study found a marked reduction in vaccine serotype carriage after PCV7 implementation. The overall pneumococcal, H. influenzae and S. aureus carriage decreased slightly, but not significantly.